141 related articles for article (PubMed ID: 38241616)
1. Targeted Therapy and Immunotherapy for Advanced Malignant Conjunctival Tumors: Systematic Review.
Serbest Ceylanoglu K; Guneri Beser B; Singalavanija T; Juntipwong S; Worden FP; Demirci H
Ophthalmic Plast Reconstr Surg; 2024 Jan-Feb 01; 40(1):18-29. PubMed ID: 38241616
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapy With Programmed Cell Death 1 Inhibitors for 5 Patients With Conjunctival Melanoma.
Sagiv O; Thakar SD; Kandl TJ; Ford J; Sniegowski MC; Hwu WJ; Esmaeli B
JAMA Ophthalmol; 2018 Nov; 136(11):1236-1241. PubMed ID: 30352118
[TBL] [Abstract][Full Text] [Related]
3. [Prognosis of primary malignant tumors of the conjunctiva].
Chebbi A; Bouguila H; Boukari M; Lajmi H; Bouzain M; Abess I; Malek I; Mrad K; Zeghal I; Nacef L
J Fr Ophtalmol; 2015 Jun; 38(6):477-85. PubMed ID: 25976134
[TBL] [Abstract][Full Text] [Related]
4. [Adjuvant therapy and interdisciplinary follow-up care of conjunctival melanoma].
Heindl LM; Koch KR; Schlaak M; Mauch C; Cursiefen C
Ophthalmologe; 2015 Nov; 112(11):907-11. PubMed ID: 26502167
[TBL] [Abstract][Full Text] [Related]
5. Systemic Rituximab Immunotherapy in the Management of Primary Ocular Adnexal Lymphoma: Single Institution Experience.
Tuncer S; Tanyıldız B; Basaran M; Buyukbabani N; Dogan O
Curr Eye Res; 2015; 40(8):780-5. PubMed ID: 25247376
[TBL] [Abstract][Full Text] [Related]
6. [Conjunctival malignancies].
Auw-Hädrich C; Reinhard T
Ophthalmologe; 2019 Oct; 116(10):989-1004. PubMed ID: 31552469
[TBL] [Abstract][Full Text] [Related]
7. Checkpoint inhibition immunotherapy for advanced local and systemic conjunctival melanoma: a clinical case series.
Finger PT; Pavlick AC
J Immunother Cancer; 2019 Mar; 7(1):83. PubMed ID: 30909967
[TBL] [Abstract][Full Text] [Related]
8. Enhanced TKTL1 expression in malignant tumors of the ocular adnexa predicts clinical outcome.
Lange CA; Tisch-Rottensteiner J; Böhringer D; Martin G; Schwartzkopff J; Auw-Haedrich C
Ophthalmology; 2012 Sep; 119(9):1924-9. PubMed ID: 22658715
[TBL] [Abstract][Full Text] [Related]
9. Conjunctival Melanoma: Current Treatments and Future Options.
Grimes JM; Shah NV; Samie FH; Carvajal RD; Marr BP
Am J Clin Dermatol; 2020 Jun; 21(3):371-381. PubMed ID: 31965542
[TBL] [Abstract][Full Text] [Related]
10. Conjunctival Tumors: Review of Clinical Features, Risks, Biomarkers, and Outcomes--The 2017 J. Donald M. Gass Lecture.
Shields CL; Chien JL; Surakiatchanukul T; Sioufi K; Lally SE; Shields JA
Asia Pac J Ophthalmol (Phila); 2017; 6(2):109-120. PubMed ID: 28399347
[TBL] [Abstract][Full Text] [Related]
11. Clinical treatment options for early-stage and advanced conjunctival melanoma.
Zeng Y; Hu C; Shu L; Pan Y; Zhao L; Pu X; Wu F
Surv Ophthalmol; 2021; 66(3):461-470. PubMed ID: 32980421
[TBL] [Abstract][Full Text] [Related]
12. Durable complete responses off all treatment in patients with metastatic malignant melanoma after sequential immunotherapy followed by a finite course of BRAF inhibitor therapy.
Wyluda EJ; Cheng J; Schell TD; Haley JS; Mallon C; Neves RI; Robertson G; Sivik J; Mackley H; Talamo G; Drabick JJ
Cancer Biol Ther; 2015; 16(5):662-70. PubMed ID: 25806780
[TBL] [Abstract][Full Text] [Related]
13. Rituximab for treatment of advanced extranodal marginal zone B cell lymphoma of the mucosa-associated lymphoid tissue lymphoma.
Raderer M; Jäger G; Brugger S; Püspök A; Fiebiger W; Drach J; Wotherspoon A; Chott A
Oncology; 2003; 65(4):306-10. PubMed ID: 14707449
[TBL] [Abstract][Full Text] [Related]
14. Genetic characterization of advanced conjunctival melanoma and response to systemic treatment.
Lodde GC; Jansen P; Möller I; Sucker A; Hassel JC; Forschner A; Eckardt J; Meier F; Reinhardt L; Kähler KC; Ziemer M; Schlaak M; Rahimi F; Schatton K; Meiss F; Gutzmer R; Pföhler C; Terheyden P; Schilling B; Sachse M; Heppt MV; Sindrilaru A; Leiter U; Zaremba A; Thielmann CM; Ugurel S; Zimmer L; Hadaschik E; Bechrakis NE; Schadendorf D; Westekemper H; Livingstone E; Griewank KG;
Eur J Cancer; 2022 May; 166():60-72. PubMed ID: 35279471
[TBL] [Abstract][Full Text] [Related]
15. A Case Report of Conjunctival Extranodal Marginal Zone Lymphoma Treated with Intralesional Rituximab Injection Therapy.
Yazicioglu T; Oklar M; Kocabas S; Karadag E; Elibol V; Tezcan ME
Ocul Immunol Inflamm; 2022 Aug; 30(6):1329-1333. PubMed ID: 36084297
[TBL] [Abstract][Full Text] [Related]
16. Invasive conjunctival melanoma mimicking ocular surface squamous neoplasia: a case series.
Gallo B; Thaung C; Hay G; Arora AK; Cohen VM; Damato B; Sagoo MS
Br J Ophthalmol; 2021 Jun; 105(6):775-778. PubMed ID: 32675060
[TBL] [Abstract][Full Text] [Related]
17. Giant ocular surface squamous neoplasia managed with interferon alpha-2b as immunotherapy or immunoreduction.
Kim HJ; Shields CL; Shah SU; Kaliki S; Lally SE
Ophthalmology; 2012 May; 119(5):938-44. PubMed ID: 22361315
[TBL] [Abstract][Full Text] [Related]
18. Squamous carcinoma and dysplasia of the conjunctiva and cornea: an analysis of 101 cases.
Yousef YA; Finger PT
Ophthalmology; 2012 Feb; 119(2):233-40. PubMed ID: 22189448
[TBL] [Abstract][Full Text] [Related]
19. Discontinuation of anti-PD1 in advanced melanoma: an observational retrospective study from the Italian Melanoma Intergroup.
Rubatto M; Fava P; Stanganelli I; Ribero S; Pigozzo J; Di Giacomo AM; Ridolfi L; Tronconi MC; Trojaniello C; Bersanelli M; Garutti M; Indini A; De Risi I; De Tursi M; Merelli B; Morgese F; Occelli M; Cappellini GCA; Poletto S; Fedele D; Brugnara S; Frisinghelli M; Formisano L; Conca R; Tucci M; Russillo M; Ceroni L; Queirolo P; Targato G; Strippoli S; Mandalà M; Guida M; Quaglino P
Eur J Cancer; 2023 Jul; 187():25-35. PubMed ID: 37099946
[TBL] [Abstract][Full Text] [Related]
20. Malignant conjunctival tumors invading the orbit.
Gökmen Soysal H; Ardiç F
Ophthalmologica; 2008; 222(5):338-43. PubMed ID: 18635931
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
